Why the study?
Does adjuvant CNF combination therapy cause significant toxicity in women with breast cancer?
Does adjuvant CNF combination therapy cause significant toxicity in women with breast cancer?
Adjuvant CNF combination therapy is well tolerated in breast cancer patients without inducing cardiotoxicity.
Answers are grounded in this paper and cite their sources.
CNF may warrant evaluation in cardiotoxicity-vulnerable patients; leaves open whether randomized trials confirm adjuvant utility.
In this study 194 women with breast cancer received adjuvant CNF combination therapy (cyclophosphamide, mitoxantrone and 5-fluorouracil). The side effects and acute toxicity of the regimen were recorded. Although myelosuppression is the dose-limiting factor of the CNF regimen, it was well tolerated and side effects were limited. This regimen induced no cardiotoxicity or irreversible alopecia. It is concluded that CNF is suitable as adjuvant chemotherapy for breast cancer patients.
No takes yet. Share an insight, caveat, or question.
Hirvikoski et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: